SCHEMBL3753376

SCHEMBL3753376

CN1CCN(Cc2cccc(COc3nccc(C(C#N)c4nc5ccccc5s4)n3)c2)CC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 11/20 0.70
MAPK9 P45984 10/20 0.70
MAPK8 P45983 2/20 0.70
RAB9A P51151 4/20 0.38
TP53 P04637 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HIF1A Q16665 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
THPO P40225 1/20 0.38
MTOR P42345 1/20 0.38
NPC1 O15118 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CHKA P35790 1/20 0.35
ACP1 P24666 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3748955 0.93 MAPK10 (0.81) MAPK10MAPK9MAPK8RAB9ATP53
SCHEMBL3747240 0.92 MAPK10 (0.72) MAPK10MAPK9MAPK8RAB9ATP53
SCHEMBL3747858 0.90 MAPK10 (0.86) MAPK10MAPK9MAPK8RAB9ATP53
SCHEMBL3740598 0.88 MAPK10 (0.85) MAPK10MAPK9MAPK8RAB9ATP53
SCHEMBL2885027 0.85 MAPK10 (0.76) MAPK10MAPK9MAPK8SMN1; SMN2MEN1
SCHEMBL3750843 0.85 MAPK10 (0.66) MAPK10MAPK9MAPK8MEN1KMT2A
SCHEMBL4200034 0.84 MAPK10 (0.84) MAPK10MAPK9MAPK8RAB9ATP53
SCHEMBL3741823 0.83 MAPK10 (0.70) MAPK10MAPK9MAPK8
SCHEMBL3746727 0.83 MAPK10 (0.79) MAPK10MAPK9MAPK8RAB9ASMN1; SMN2
SCHEMBL15920643 0.83 MAPK9 (0.66) MAPK10MAPK9MAPK8RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7838522-B2 Benzothiazole formulations and use thereof ARES TRADING S.A. (CH) 2010-11-23 US disclosed
US-7838522-B2 Benzothiazole formulations and use thereof ARES TRADING S.A. (CH) 2010-11-23 US disclosed
US-7838522-B2 Benzothiazole formulations and use thereof ARES TRADING S.A. (CH) 2010-11-23 US disclosed
EP-1812072-B1 BENZOTHIAZOLE FORMULATIONS AND USE THEREOF ARES TRADING SA (CH) 2008-10-22 EP disclosed
US-20080051397-A1 Benzothiazole Formulations and Use Thereof ARES TRADING S.A. (CH) 2008-02-28 US disclosed
US-20080051397-A1 Benzothiazole Formulations and Use Thereof ARES TRADING S.A. (CH) 2008-02-28 US disclosed
US-20080051397-A1 Benzothiazole Formulations and Use Thereof ARES TRADING S.A. (CH) 2008-02-28 US disclosed
EP-1812072-A2 BENZOTHIAZOLE FORMULATIONS AND USE THEREOF Ares Trading S.A. (CH) 2007-08-01 EP disclosed
WO-2006053882-A2 BENZOTHIAZOLE FORMULATIONS AND USE THEREOF ARES TRADING S.A. (CH) 2006-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051397-A1 Benzothiazole Formulations and Use Thereof MGLL, MBOAT4, MBOAT1 MAPK10 3176/4885MAPK9 3960/4885MAPK8 4361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.